Their findings as aligned with previous cohort studies, showing that plasma GFAP was incrementally increased along the course of Alzheimer’s disease from preclinical and prodromal stages to Alzheimer’s disease dementia (P < 0.001). The gene discussed is GFAP; the disease is Alzheimer disease.